Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab Plus CAMPATH in Relapsed/Refractory Low-Grade Follicular NHL
NCT00077961Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Dec 2003
- Primary completion
- Feb 2006
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in follicular lymphoma (FL), sponsored by Sanofi. Primary endpoints: Safety, Maximum Tolerated Dose and 1 more. Started Dec 2003; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00077961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077961.